Bosutinib in chronic myeloid leukemia: patient selection and perspectives

References

• PuttiniMColucciaAMBoschelliFIn vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cellsCancer Res20066623113141132217114238
   PubMed Web of Science ®Google Scholar
• Remsing RixLLRixUColingeJGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cellsLeukemia200923347748519039322
   PubMed Web of Science ®Google Scholar
• GolasJMArndtKEtienneCSKI-606, a 4-anilino-3-quinolin-ecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude miceCancer Res200363237538112543790
   PubMed Web of Science ®Google Scholar
• AbbasRHsyuPHClinical pharmacokinetics and pharmacodynamics of bosutinibClin Pharmacokinet201655101191120427113346
   PubMed Web of Science ®Google Scholar
• LevinsonNMBoxerSGStructural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domainPLoS One201274e2982822493660
   PubMed Web of Science ®Google Scholar
• AmsbergGKKoschmiederSProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaOnco Targets Ther201369910623493838
   PubMed Web of Science ®Google Scholar
• CortesJEGambacorti-PasseriniCKimDWEffects of bosutinib treatment on renal function in patients with Philadelphia Chromosome-Positive LeukemiasClin Lymphoma Myeloma Leuk2017171068469528807791
   PubMed Web of Science ®Google Scholar
• KhouryHJCortesJEKantarjianHMBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood2012119153403341222371878
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCBrummendorfTHKimDWBosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-upAm J Hematol201489773274224711212
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCKantarjianHMKimDWLong-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitorsAm J Hematol201590975576826040495
   PubMed Web of Science ®Google Scholar
• AtillaEAtacaPOzyurekEErdenIGurmanGSuccessful bosutinib experience in an elderly acute lymphoblastic leukemia patient with suspected central nervous system involvement transformed from chronic myeloid leukemiaCase Rep Hematol2015201568942326697241
   PubMedGoogle Scholar
• WhiteleyJReismanAShapiroMCortesJCellaDHealth-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failureCurr Med Res Opin20163281325133427045164
   PubMed Web of Science ®Google Scholar
• CortesJEKhouryHJKantarjianHMLong-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinibAm J Hematol201691121206121427531525
   PubMed Web of Science ®Google Scholar
• BrümmendorfTHGambacorti-PasseriniCKimDW900 Second-line bosutinib in patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: an 8-year update [Abstract]ASH Annual Meeting 2017December 11
   Google Scholar
• CortesJEKantarjianHMBrummendorfTHSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood2011118174567457621865346
   PubMed Web of Science ®Google Scholar
• BrümmendorfTHCortesJEKhouryHJFactors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibBr J Haematol201617219711026537529
   PubMed Web of Science ®Google Scholar
• TraskPCCellaDBessonNKellyVMassziTKimDWHealth-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemiaLeuk Res201236443844222036634
   PubMed Web of Science ®Google Scholar
• Garcia-GutierrezVMartinez-TrillosALopez LorenzoJLBosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use programAm J Hematol201590542943325683327
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWKantarjianHMBrummendorfTHBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trialJ Clin Oncol201230283486349222949154
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCCortesJELiptonJHSafety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemiaAm J Hematol2014891094795324944159
   PubMed Web of Science ®Google Scholar
• BrummendorfTHCortesJEde SouzaCABosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trialBr J Haematol20151681698125196702
   PubMed Web of Science ®Google Scholar
• CortesJEJean KhouryHKantarjianHLong-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibAm J Hematol201691660661626971533
   PubMed Web of Science ®Google Scholar
• CortesJEGambacorti-PasseriniCDeiningerMWBosutinib versus imatinib for newly diagnosed chronic myeloid leu-kemia: results from the randomized BFORE trialJ Clin Oncol2017JCO2017747162
   Web of Science ®Google Scholar
• Gambacorti-PasseriniC DMMauroMJChuahCBosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up [Abstract]ASH Annual Meeting 2017December 11
   Google Scholar
• Gambacorti-PasseriniCAroldiACordaniNPiazzaRChronic myeloid leukemia: second-line drugs of choiceAm J Hematol2016911677526588811
   PubMed Web of Science ®Google Scholar
• AultPSRose PharmDJNodzon PhDLKaledESBosutinib therapy in patients with chronic myeloid leukemia: practical considerations for management of side effectsJ Adv Pract Oncol20167216017528090366
   PubMedGoogle Scholar
• IsfortSKeller-v AmsbergGSchafhausenPKoschmiederSBrummendorfTHBosutinib: a novel second-generation tyrosine kinase inhibitorRecent Results Cancer Res2014201819724756786
   PubMedGoogle Scholar
• BartolovicKBalabanovSHartmannUInhibitory effect of imatinib on normal progenitor cells in vitroBlood2004103252352912969987
   PubMed Web of Science ®Google Scholar
• KreutzmanAKoskenvesaPTiinaKImmunological monitoring of CML patients during first-line bosutinib and imatinib treatmentBlood20161283069
   Web of Science ®Google Scholar
• KalmantiLSausseleSLausekerMSafety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVLeukemia20152951123113225676422
   PubMed Web of Science ®Google Scholar
• HochhausASaglioGHughesTPLong-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia20163051044105426837842
   PubMed Web of Science ®Google Scholar
• CortesJEJimenezCAMauroMJGeyerAPinilla-IbarzJSmithBDPleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and managementClin Lymphoma Myeloma Leuk2017172788228082112
   PubMed Web of Science ®Google Scholar
• HehlmannRLausekerMSausseleSAssessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsLeukemia201731112398240628804124
   PubMed Web of Science ®Google Scholar
• AbbasRLeisterCSonnichsenDA clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjectsClin Drug Inves-tig2013338589595
   Web of Science ®Google Scholar
• HsyuPHPignataroDSMatschkeKEffect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjectsEur J Clin Pharmacol2017731495627718000
   PubMed Web of Science ®Google Scholar
• OnoCHsyuPHAbbasRLoiCMYamazakiSApplication of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: prediction of drug-drug and drug-disease interactionsDrug Metab Dispos201745439039828167538
   PubMed Web of Science ®Google Scholar
• MuresanBMamoloCCappelleriJCMatching-adjusted indirect treatment comparison of bosutinib, dasatinib, nilotinib and ponatinib on survival for second line chronic phase chronic myeloid leukemia patientsBlood20161283095
   Web of Science ®Google Scholar
• KantarjianHMHochhausASaglioGNilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialLancet Oncol201112984185121856226
   PubMed Web of Science ®Google Scholar
• KantarjianHMShahNPCortesJEDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood201211951123112922160483
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFJBhallaKNNilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 studyHaema-tologica2009254
   Google Scholar
• KantarjianHPasquiniRLevyVDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Cancer2009115184136414719536906
   PubMed Web of Science ®Google Scholar
• WolfDBrümmendorfTHIsfortSIndividualisierte Therapie der CML: Bedeutung patienten- und krankheitsspezifischer Parameter für eine optimale Therapiewahl. [Individualized therapy for CML: importance of patient- and illness- specific parameters in order to choose the optimal therapy]Thieme Praxis Report201579 German
   Google Scholar
• SteegmannJLBaccaraniMBrecciaMEuropean leukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLeukemia20163081648167127121688
   PubMed Web of Science ®Google Scholar
• KotaVGambacorti-PasseriniCCortsJEEfficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive chronic myeloid leukemiaBlood20161281921
   Web of Science ®Google Scholar
• KongJHKhouryHJKimASHillBGKotaVThe safety of Bosutinib for the treatment of chronic myeloid leukemiaExpert Opin Drug Saf201716101203120928774214
   PubMed Web of Science ®Google Scholar